Dotarem® (gadoterate meglumine) Injection Now Offered Via Innovative Technology Agreement Awarded By Novation

07.11.2013 13:57

Guerbet LLC, USA (November 06, 2013)

Guerbet announced today that Novation, the leading health care supply chain expertise, analytics and contracting company, has awarded a new agreement for Dotarem® (gadoterate meglumine) Injection, a gadolinium-based contrast agent (GBCA) indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier and/or abnormal vascularity.  Click here to read the press release.